BO1 Stock Overview
A biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
BioCryst Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.02 |
| 52 Week High | US$8.93 |
| 52 Week Low | US$3.84 |
| Beta | 1.85 |
| 1 Month Change | -16.31% |
| 3 Month Change | -0.96% |
| 1 Year Change | 51.46% |
| 3 Year Change | -53.09% |
| 5 Year Change | 294.38% |
| Change since IPO | 53.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| BO1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.0% | 3.4% | 4.1% |
| 1Y | 51.5% | -10.0% | 17.2% |
Return vs Industry: BO1 exceeded the German Biotechs industry which returned -9.2% over the past year.
Return vs Market: BO1 exceeded the German Market which returned 16.4% over the past year.
Price Volatility
| BO1 volatility | |
|---|---|
| BO1 Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: BO1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BO1's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 580 | Jon Stonehouse | www.biocryst.com |
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor.
BioCryst Pharmaceuticals, Inc. Fundamentals Summary
| BO1 fundamental statistics | |
|---|---|
| Market cap | €1.48b |
| Earnings (TTM) | -€81.19m |
| Revenue (TTM) | €411.73m |
3.5x
P/S Ratio-18.0x
P/E RatioIs BO1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BO1 income statement (TTM) | |
|---|---|
| Revenue | US$450.71m |
| Cost of Revenue | US$185.92m |
| Gross Profit | US$264.79m |
| Other Expenses | US$353.67m |
| Earnings | -US$88.88m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 58.75% |
| Net Profit Margin | -19.72% |
| Debt/Equity Ratio | -174.1% |
How did BO1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/18 23:57 |
| End of Day Share Price | 2025/03/18 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioCryst Pharmaceuticals, Inc. is covered by 30 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |